Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
ABT‑494 is an oral selective JAK1 inhibitor that is being developed for treatment of rheumatoid arthritis and Crohn’s disease. ABT-494 is metabolized by cytochrome P450 (CYP) enzymes including CYP3A and approximately 20% of the dose is eliminated unchanged in urine. The objectives of this work were to assess the effect of high-fat meal, ketoconazole (a strong CYP3A inhibitor), and rifampin (a broad CYP inducer and an OATP1B inhibitor) on the pharmacokinetics of ABT-494 in humans.
Two studies were conducted. In the first study, using a randomized, two sequence, cross-over design, healthy adult subjects (N = 12) received a single dose of 3 mg ABT-494 in three different occasions: after 10 hours of fasting, 30 minutes after starting a high-fat breakfast, and on Day 4 of a 6-day regimen of once daily ketoconazole (400 mg) under fasting condition. In the second study, healthy adult subjects (N = 12) received single doses of 12 mg ABT-494 on three sequential occasions: alone, with the 1st, and with the 8thdose of a 9-day regimen of once daily rifampin (600 mg). Serial blood samples were collected to determine ABT-494 plasma concentrations and safety and tolerability were monitored. Pharmacokinetic parameters for ABT-494 were calculated using non-compartmental analyses.
Relative to administration under fasting conditions, high-fat meal delayed ABT-494 Tmax by approximately 1 hour, decreased ABT-494 Cmax by 23% and had no impact on ABT-494 AUC. Administration of ABT-494 with repeated doses of ketoconazole increased ABT-494 Cmax and AUC by 70% and 75%, respectively. Repeat-dose administration of rifampin decreased ABT-494 Cmaxand AUC by 51% and 61%, respectively, whereas single dose co-administration of rifampin had no effect on ABT-494 AUC. ABT-494 was well tolerated by subjects.
Food has no clinically meaningful effect on ABT-494 plasma exposure. Strong inhibition of CYP3A results in a limited increase in ABT-494 exposure (i.e. weak pharmacokinetic interaction). The broad CYP inducer rifampin reduces ABT-494 exposure by approximately half, while lack of effect of the first dose of rifampin on ABT-494 AUC suggests no interaction of ABT-494 with OATP1B inhibitors.
To cite this abstract in AMA style:Mohamed ME, Jungerwirth S, Asatryan A, Jiang P, Othman A. Assessment of the Effect of CYP3A Inhibition, CYP Induction, OATP1B Inhibition and Administration of High-Fat Meal on the Pharmacokinetics of the Potent and Selective JAK1 Inhibitor ABT-494 [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/assessment-of-the-effect-of-cyp3a-inhibition-cyp-induction-oatp1b-inhibition-and-administration-of-high-fat-meal-on-the-pharmacokinetics-of-the-potent-and-selective-jak1-inhibitor-abt-494/. Accessed January 19, 2020.
« Back to 2015 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-the-effect-of-cyp3a-inhibition-cyp-induction-oatp1b-inhibition-and-administration-of-high-fat-meal-on-the-pharmacokinetics-of-the-potent-and-selective-jak1-inhibitor-abt-494/